Sunshine Biopharma INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Sunshine Biopharma Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing revenues of $36.3 million and a net loss of $5.98 million.
NASDAQ
Sunshine Biopharma's 10-K filing reveals a revenue increase driven by expanded generic drug sales in Canada, but the company still reports a net loss for the year ended December 31, 2024.
NASDAQ
10-K: Sunshine Biopharma Reports Full Year 2023 Results, Revenue Surges Following Nora Pharma Acquisition
Sunshine Biopharma's 2023 revenue significantly increased due to the inclusion of a full year of sales from its subsidiary, Nora Pharma, though the company still reported a net loss.